Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Average Recommendation of “Moderate Buy” from Analysts

Sana Biotechnology, Inc. (NASDAQ:SANA) has earned an average rating of “Moderate Buy” from the nine research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $9.50.

SANA has been the subject of several recent research reports. Wall Street Zen downgraded Sana Biotechnology from a “hold” rating to a “sell” rating in a report on Sunday, June 7th. Morgan Stanley reiterated an “overweight” rating and issued a $12.00 price target on shares of Sana Biotechnology in a research note on Friday, March 13th. Weiss Ratings lowered Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. Rodman & Renshaw assumed coverage on Sana Biotechnology in a research note on Monday, May 11th. They set a “buy” rating and a $16.00 target price for the company. Finally, Wedbush lifted their price target on shares of Sana Biotechnology from $6.00 to $7.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 14th.

Hedge Funds Weigh In On Sana Biotechnology

Large investors have recently bought and sold shares of the stock. AQR Capital Management LLC boosted its holdings in shares of Sana Biotechnology by 49.8% in the first quarter. AQR Capital Management LLC now owns 573,146 shares of the company’s stock valued at $963,000 after acquiring an additional 190,483 shares in the last quarter. Woodline Partners LP increased its position in shares of Sana Biotechnology by 13.1% during the 1st quarter. Woodline Partners LP now owns 780,656 shares of the company’s stock valued at $1,312,000 after purchasing an additional 90,515 shares during the period. Franklin Resources Inc. raised its stake in shares of Sana Biotechnology by 86.8% in the 2nd quarter. Franklin Resources Inc. now owns 93,081 shares of the company’s stock worth $254,000 after buying an additional 43,247 shares in the last quarter. Rhumbline Advisers boosted its stake in Sana Biotechnology by 11.6% during the second quarter. Rhumbline Advisers now owns 203,283 shares of the company’s stock valued at $555,000 after buying an additional 21,149 shares in the last quarter. Finally, Prudential Financial Inc. acquired a new position in Sana Biotechnology during the second quarter worth about $50,000. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Price Performance

Shares of NASDAQ SANA opened at $3.91 on Thursday. The company has a market cap of $1.09 billion, a PE ratio of -4.20 and a beta of 2.13. Sana Biotechnology has a 12 month low of $2.61 and a 12 month high of $6.55. The company has a 50-day simple moving average of $3.22 and a 200-day simple moving average of $3.66.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01. On average, analysts anticipate that Sana Biotechnology will post -0.59 EPS for the current year.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.